232 related articles for article (PubMed ID: 19308291)
1. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
Simon DP; Vadakkadath Meethal S; Wilson AC; Gallego MJ; Weinecke SL; Bruce E; Lyons PF; Haasl RJ; Bowen RL; Atwood CS
Neoplasia; 2009 Apr; 11(4):365-76. PubMed ID: 19308291
[TBL] [Abstract][Full Text] [Related]
2. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
3. Activin type II receptor signaling in cardiac aging and heart failure.
Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
[TBL] [Abstract][Full Text] [Related]
4. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
5. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
[TBL] [Abstract][Full Text] [Related]
6. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent activin receptor expression pinpoints activin A as a physiological regulator of rat Sertoli cell proliferation.
Fragale A; Puglisi R; Morena AR; Stefanini M; Boitani C
Mol Hum Reprod; 2001 Dec; 7(12):1107-14. PubMed ID: 11719587
[TBL] [Abstract][Full Text] [Related]
8. Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway.
Shi Y; Bao YL; Wu Y; Yu CL; Huang YX; Sun Y; Zheng LH; Li YX
J Biomol Screen; 2011 Jun; 16(5):525-35. PubMed ID: 21378277
[TBL] [Abstract][Full Text] [Related]
9. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β.
Ungefroren H; Hyder A; Hinz H; Groth S; Lange H; El-Sayed KM; Ehnert S; Nüssler AK; Fändrich F; Gieseler F
PLoS One; 2015; 10(2):e0118097. PubMed ID: 25707005
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial lineages.
Li Q; Karam SM; Coerver KA; Matzuk MM; Gordon JI
Mol Endocrinol; 1998 Feb; 12(2):181-92. PubMed ID: 9482661
[TBL] [Abstract][Full Text] [Related]
11. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
Harrison CA; Chan KL; Robertson DM
Endocrinology; 2006 Jun; 147(6):2744-53. PubMed ID: 16527838
[TBL] [Abstract][Full Text] [Related]
12. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
Lewis KA; Gray PC; Blount AL; MacConell LA; Wiater E; Bilezikjian LM; Vale W
Nature; 2000 Mar; 404(6776):411-4. PubMed ID: 10746731
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
14. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
15. Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
Donaldson CJ; Vaughan JM; Corrigan AZ; Fischer WH; Vale WW
Endocrinology; 1999 Apr; 140(4):1760-6. PubMed ID: 10098513
[TBL] [Abstract][Full Text] [Related]
16. Novel factors in regulation of activin signaling.
Tsuchida K; Nakatani M; Matsuzaki T; Yamakawa N; Liu Z; Bao Y; Arai KY; Murakami T; Takehara Y; Kurisaki A; Sugino H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):1-8. PubMed ID: 15451561
[TBL] [Abstract][Full Text] [Related]
17. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
Leal AM; Takabe K; Wang L; Donaldson CJ; MacConell LA; Bilezikjian LM; Verma IM; Vale W
Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
[TBL] [Abstract][Full Text] [Related]
18. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
Coerver KA; Woodruff TK; Finegold MJ; Mather J; Bradley A; Matzuk MM
Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
20. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
